| Literature DB >> 35497279 |
Jiayu Xie1,2, Dapeng Zhang3, Cheng Liu2, Lingchong Wang1.
Abstract
Tubiechong, in Chinese medicine, denotes the dried female insects of Eupolyphaga sinensis Walker (ESW) or Polyphaga plancyi Bolivar (PPB). As a traditional insect-type, in medicine, it has been historically utilized to treat bruises, fractures, amenorrhea, postpartum blood stasis, lumps and relieving pain. We herein have performed a systematic survey involving the chemical and biological studies in the past decades to reveal the value of such insect resources for their development and clinical utilization. Chemical studies indicated that Tubiechong generated many active compounds, including proteins, amino acids, peptides, fatty acids, alkaloids, nucleosides, polysaccharides, fat-soluble vitamins and mineral elements. Tubiechong or its extract has a wide range of activities including anticoagulation and anti-thrombosis, anti-tumor, antioxidant, immune regulation, blood lipid regulation and hepatoprotection. Finally, a periodic mini-review was conducted to summarize such chemical and pharmacological profiles of Tubiechong medicine. The active peptides in Tubiechong are majorly focused in this review and introduced as one important aspect since there is much literature and huge investigative interest in it. Traditional medical use of the insect was also stressed in this review associating with its disease-eliminating actions by promoting blood circulation or eliminating tissue-swelling pains, which might play important roles in anticancer practices or investigation. In accordance with the modern pharmacological progress, Tubiechong and its extracts indeed exerted antitumor actions through multiple pathways, such as interfering with tumor biological behaviors (growth, apoptosis, invasion, metastasis and angiogenesis), and regulating host immune function. To some extent, this knowledge would provide a basis for further research and application of Tubiechong medicine. This journal is © The Royal Society of Chemistry.Entities:
Year: 2021 PMID: 35497279 PMCID: PMC9042404 DOI: 10.1039/d1ra05425b
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Summary of several active peptides or protein products isolated from Tubiechong medicine
| Preparing method | Products | Identification | Characterizations | Bioactivities | Potential applications | Ref. |
|---|---|---|---|---|---|---|
| Hydrolyzation of ESW with pepsin and trypsin | EPs | Crude extract | With less than 3.3 kDa of Mw, fifteen amino acids (Asp, Glu, Ser, Gly, Thr, Ala, Arg, Tyr, Val, Met, Phe, Iso, Leu, Lys and Pro) in detection | Antioxidant | Protection against photo-aging skin |
|
| Hydrolyzation of ESW with pepsin and trypsin, gel filtration & ion exchange chromatography | A4 | Purified fraction | With less Mw than EPs | Antioxidant | Protection against photo-aging of skin | |
| Hydrolyzation of ESW with arazyme protease, ultrafiltration, DEAE-cellulose chromatography |
| Purified fractions | No date | Antioxidant | Antioxidant agent |
|
| Homogenization of ESW, salting out, ultrafiltration, ion exchange, hydrophobic & gel filtration chromatographies | EPS72 | Purified protein | 72 kDa of Mw, a band in SDS–PAGE | Antitumor, anti-proliferative effect on A549 (IC50, 18.76 μg mL−1) | Protection against tumor |
|
| Homogenization of ESW, savage deproteinization, dialysis, DEAE-cellulose chromatography | Unnamed | Purified glycoprotein | 41.3 kDa of Mw, | Antitumor, Antiproliferative effect on Tea-8113 | Protection against tumor |
|
| Homogenization of ESW, salting out, DEAE-cellulose & Sephadex G-75 column chromatographies | EFP | Purified fibrinolytic peptide | No date | Anti-proliferative effect on MVEC, induce apoptosis and cause cell cycle arrest at S and G2/M phases | Anti-angiogenic agent |
|
| Homogenization of ESW, dialysis, cationic exchange, gel filtration & anionic exchange chromatographies | Eupolytin1 | Purified protein | 26 kDa of Mw, with IVGGSDANIEDLPYQLSFETIDYDVAVARVATPFSYGSGVQQLQVVSVPIVSPQQCNNDYASDPCQGDSSGPLTVGGYPGVYSNVATLR in sequence | Fibrinolytic and plasminogen-activating (PA) activities | Anti-thrombosis agent |
|
| Homogenization of ESW, salting out, DEAE-cellulose chromatography; PAGE electrophoresis | EFF-1, EFF-2, EFF-3 | Purified protein | With 41 kDa, 32.9 kDa and 30.6 kDa of Mw, respectively | Fibrinolytic activities | Fibrinolytic enzyme |
|
| Homogenization of ESW; salting out; DEAE-cellulose & gel filtration chromatographies | Unnamed | Purified glycoprotein | 41.3 kDa of Mw, 10.5% of carbohydrate content, | Fibrinolytic activities | Fibrinolytic enzyme |
|
| Water extract and alcohol precipitate, ion exchange & gel filtration chromatographies, RP-HPLC | Fraction VI | Purified fraction | 3.8 kDa of Mw, 89.3% of protein content, two bands in SDS–PAGE | Fibrinolytic activities | Fibrinolytic enzyme |
|
| Hydrolyzation of ESW with pepsin and trypsin, ultrafiltration & nanofiltration, macroporous resin, Sephadex G-25 column chromatography, RP-HPLC | DP17 | Purified peptide | 1.43 kDa of Mw, with DAVPGAGPAGCHPGAGP in sequence, 8 beta sheets and 2 alpha sheets in configuration | Lipid accumulation reducing in liver tissues, reducing blood lipids | Hypolipidemic agent |
|
| Hydrolyzation of ESW with pepsin and trypsin, ultrafiltration | APE | Crude extract | 71.05 ± 3.10% of the protein content | Blood lipid reducing activity | Hypolipidemic agent |
|
| Homogenization of ESW, gel filtration chromatography, RP-HPLC | Unnamed | Purified peptide | ACDFQQCWVTCQRQYSINFISARCNGDSCVCTFRT in sequence | Antimicrobial | Antimicrobial agent |
|
Fig. 1Sugar chain fragments found in the structural elucidation of ESPS polysaccharide isolated from ESW.
Fig. 2Chemical structures of 6 compounds identified as abundant fatty acids from TCM Tubiechong.
Fig. 3Chemical structures of some nucleoside analogs detected in ESW.
Fig. 4Chemical structures of some phenylpropanoids detected in ESW and PPB.
Fig. 5Chemical structures of some alkaloids identified from ESW and PPB.
Pharmacological activities of Tubiechong and their extracts
| Pharmacological activity | Testing substance | Tested living system/organ/cell | Dose and administration | Results | Mechanisms | Ref. |
|---|---|---|---|---|---|---|
| Anti-tumor activity | ESW 70% ethanol extract | Cultured A549 cells; cultured HUVECs; | 0.1–0.8 mg mL−1 for 48 h | Inhibited cell proliferation (IC50 of HUVECs was 0.34 mg mL−1; IC50 of A549 was 0.27 mg mL−1) and migration | Inhibited the autophosphorylation of KDR, downregulate the activation of AKT and (ERK)1/2 |
|
| ESW 70% ethanol extract (ESWE) | Cultured MDA-MB-435s and MDA-MB-231 cells | 0.4–1.6 mg mL−1 for 24 h | Inhibited cell proliferation (with 0.564 and 0.724 mg mL−1 of IC50, respectively) and migration | Inhibition the expression of MAPK signaling and related metastasis factors |
| |
| MDA-MB-231 xenograft mice model | 200, 400 mg kg−1 for 14 days | Tumor growth inhibition | ||||
| ESW 70% ethanol extract (ESEE) | K562 | 0.05–0.2 mg mL−1 for 48 h | Tumor growth inhibition, inducing G2–M phase arrest | Down-regulating phosphorylation of EGFR, AKT and ERK1/2 |
| |
| Tumor (S180)-bearing mice | 100, 200 and 400 mg kg−1 for 10 days | Tumor growth inhibition | ||||
| ESW 70% ethanol extract (ESWE) | SMMC-7721, BEL-7402 and HepG2 cells; | 0.05, 0.1, and 0.2 mg mL−1 for 48 h | Inhibited cell proliferation (with 0.13 mg mL−1, 0.14 mg mL−1 and 0.67 mg mL−1 of IC50, respectively) | Inhibited growth and metastasis signaling (the PKC, AKT, MAPK signaling and related metastasis signaling) |
| |
| SMMC-7721 xenograft in athymic mice | 400 mg kg−1 for 10 days | Tumor growth inhibition | ||||
| ESW 95% ethanol extract (ESEE) (mainly fatty acids) | Tumor (H22)-bearing mice | 31–124 mg kg−1 for 14 days | Tumor growth inhibition, promoting TNF-α and IFN-γ production and inducing apoptosis |
|
| |
| Polysaccharide from ESW(ESPS) | Spleen lymphocytes | 50, 100 and 200 μg mL−1 for 48 h | Enhanced lymphocyte activity, promoted lymphocyte proliferation | Enhancement of lymphocyte cytotoxicity |
| |
| NK cells | 100, 200 and 400 μg mL−1 for 48 h | Enhanced NK cytotoxicity | ||||
| Tumor (H22)-bearing mice | 5, 10 and 20 mg kg−1 once every two days for 15 days | Tumor growth inhibition | ||||
| Purified protein EPS72 | A549 cells | 5 and 40 μg mL−1 for 48 h | Inhibited cell proliferation (with 18.76 μg mL−1 of IC50), restrained cell migration and invasion | Inhibited cell adhesion to fibronectin and collagen IV, down-regulated the expression of β1-integrin |
| |
| ESW 80% ethanol extract (ESWE) | PC3 cells | 0.25 and 0.5 mg mL−1 for 24 h | Inhibited the growth, migration and invasion of PC3 cells | MMP-2 and MMP-9 expression inhibition |
| |
| ESW 95% ethanol extract (ESE) | HepG2 and SGC-7901 cells | 0.1–0.535 μg mL−1 for 48 h | Inhibited cell proliferation (with 0.90 and 0.11 μg mL−1 of IC50, respectively), induce HepG2 cell apoptosis | No mention |
| |
| Protein of ESW (EFP) containing serum | A549 cells | Serum drug from 0.73–2.90 mg kg−1 for 48 h | Tumor proliferation inhibition, inducing apoptosis | Increasing the ratio of Bax/Bcl-2 |
| |
| ESW fibrinolyric protein (EFP) drug serum | HepG2 and MCF-7 cells | Serum drug from 1.25 to 5 mg kg−1 for 48 h | Tumor proliferation inhibition, inhibiting angiogenesis | Down-regulating the expression of VEGF and bFGF |
| |
| Serum containing ESW | HepG2 cells | 20% ESW serum for 72 hours | Tumor proliferation inhibition | Inducing G0–G1 phase arrest |
| |
| Purified protein from ESW | Tea-8113 cells | 0.010–0.0902g mL−1 for 72 h | Tumor proliferation inhibition | No mention |
| |
| Neolignans from PPB | K562, A549, and Huh7 cells | 2.5–40 μM for 48 h | Phenylpropanoids compound 9 inhibited cell proliferation of Huh-7 cells (with 23.2 μM and 27.1 μM of IC50, respectively), and inhibited cell proliferation of K562, A549 | No mention |
| |
| Anti- thrombogenic and anticoagulant activities | Three kinds (EFF-1, EFF-2 and EFF-3) of fibrinolytic factors from ESW | Fibrin plate experiment | 20 μL per well | Activated plasminogen | No mention |
|
| Purified protein from ESW (eupolytin1) | Arteriovenous shunt rat models | 0.06 μmol kg−1 | Reduced thrombus weight | No mention |
| |
| Fraction from ESW (fraction VI) | Fibrin plate experiment | 5–20 μL per well | Degraded fibrin and activated the plasminogen | No mention |
| |
| ESW fibrinolytic protein (EFP) | Carrageenan-induced thrombosis model mice | 4,8,16 g kg−1 d−1 for 10 days | Reduce the length of thrombus | No mention |
| |
| Immunomodulatory activity | Decoction of ESW | Healthy mice | 1.89–7.56 g kg−1 d−1 to mice for 4 weeks | Enhanced the carbon expurgatory index and phagocytic index | No mention |
|
| Papain-hydrolyzed peptides of ESW | Healthy mice | 0.3 g kg−1 d−1 to mice for 10 days | Increased index of thymus and spleen, enhanced the phagocytic function of macrophage and promoted the level of IL-2 in serum | No mention |
| |
| ESW lyophilized powder (ESL) | Immunosuppressed mice induced by cyclophosphamide | 0.5, 1.0 and 2.0 g kg−1 d−1 for 14 days | Increased the immune organ index, mononuclear macrophages function and the level of NK cell | Down-regulated the phosphorylation of JNK and the Bax/Bcl-2 ratio |
| |
| Hepatoprotective activity | ESW polypeptides | CCl4-induced chronic liver injury mice | 50, 100 and 200 mg kg−1 d−1 for 6 weeks | Attenuates CCl4-induced chronic liver injury in mice | Down-regulated the expression of Bax, caspase-3,α-SMA and TGF-β1 |
|
| Anti-oxidative and anti-aging activities | Arazyme enzymatic hydrolysis peptides of ESW |
| 300 mg kg−1 d−1 for 6 weeks | Scavenge free radicals | No mention |
|
| Polypeptide extracts of ESW |
| 0, 40, 80, 160 mg kg−1d for 20 days | Enhanced the anti-stress and antioxidative capacity, delayed the oxidative aging | Initiating Nrf2-ARE antioxidant signaling pathway |
| |
| Peptides from the enzymatic hydrolysate of ESW( | Free radicals |
| Scavenge free radicals | No mention |
| |
| Enzymatic hydrolysis products of ESW (EPs) | UV radiation-induced skin photoaging mice | Daubed with 140 μL of EPs at a dose of 25, 50 and 75 mg mL−1 per day for 8 weeks | Improved UV irradiation-induced damage of skin texture and morphology | Enhanced the activities of SOD, CAT and GPH-Px, increased the contents of HYP, and reduced the content of MDA in skin |
|
Fig. 6Some anti-tumor actions and mechanisms of Tubiechong and its extracts.